This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in JAMA  Social Bookmarking   What's this?

Integrin ₃ Blockade With Abciximab and Protection From Myocardial Ischemic Events

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor.—As reported by Dr Topol and colleagues¹ and Drs Fischman and Savage,² the mechanism by which the blockage of ₃ integrin with abciximab results in improved cardiac preservation is unclear. We suggest a possibility not mentioned in their speculations: ₃ integrin was shown to be a mediator in the transport of iron into cells independent of transferrin. Therefore, blockage of ₃ integrin might be expected to reduce intracellular concentrations of iron.^3-4 Iron mediates free radical formation and reperfusion injury. Iron chelators such as desferrioxamine, which diminish iron transport into cells, have a protective effect on cardiac damage during reperfusion⁵ and may be analogous to the use of substances that impair uptake of iron into cells by ₃ integrin. Protection of the cell from exposure to iron may be an important factor in the beneficial results of ₃ integrin blockage as reported by Topol et al.¹

Marcel E. Conrad, MD; Jay N. Umbreit, . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention
Eric J. Topol, James J. Ferguson, Harlan F. Weisman, James E. Tcheng, Stephen G. Ellis, Neal S. Kleiman, Russell J. Ivanhoe, Ann L. Wang, David P. Miller, Keaven M. Anderson, and Robert M. Califf
JAMA. 1997;278(6):479-484.
ABSTRACT